HK Stock Market Move | HENLIUS (02696) rose more than 8% in early trading, with the stock price hitting a new all-time high again. Fute Ning's first prescription was successfully implemented in various regions across the country.

HENLIUS (02696) rose more than 8%, hitting a record high of 89 Hong Kong dollars, as of the time of writing, up 5.31% to 86.2 Hong Kong dollars, with a turnover of 73.6475 million Hong Kong dollars. On the news front, HENLIUS announced that its innovative small molecule CDK4/6 inhibitor, Fertinib (palbociclib citrate capsules), has issued its first prescription. In recent days, it has been prescribed by more than ten hospitals including Fudan University Affiliated Tumor Hospital, Chinese Academy of Medical Sciences Tumor Hospital, Zhejiang University School of Medicine Affiliated First Hospital, Anhui Medical University Affiliated First Hospital, Shandong Tumor Hospital, Shanghai Tenth People's Hospital, Nanjing Gulou Hospital, and Qingdao University Affiliated Hospital, among others, across the country. It is reported that Fertinib in combination with fulvestrant can be used for HR-positive and HER2-negative recurrent or metastatic adult breast cancer patients with disease progression after prior endocrine therapy. HENLIUS stated that the drug, owned by Shanghai Fosun Pharmaceutical member company Jinzhou Aohong Pharmaceuticals, has independent intellectual property rights and its commercialization in China is managed by HENLIUS.